Advertisement

Epigenetic Markers of Prognosis in Melanoma

Protocol
First Online:
Part of the Methods in Molecular Biology book series (MIMB, volume 1102)

Abstract

Prognostic molecular markers are urgently needed for allowing to discriminate the clinical course of disease of melanoma patients, which is highly heterogeneous and unpredictable also within a specific clinicopathological stage and substage of disease. Alterations in DNA methylation have been reported to be widely present in cutaneous melanoma, profoundly impacting its biology. In line with this notion, we have identified methylation markers as independent prognostic factors in stage IIIC melanoma patients. In this chapter we describe the measurement of the methylation of the Long Interspersed Nucleotide Element-1 sequences in laser capture microdissected tumor tissues as a prognostic tool in stage III melanoma patients, which could help in achieving a more appropriate and patient-tailored clinical management of cutaneous melanoma.

Key words

DNA methylation Epigenetic Long Interspersed Nucleotide Element-1 Repetitive elements Methylation profiles Prognosis 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206, doi:JCO.2009.23.4799 [pii] 10.1200/JCO.2009.23.4799CrossRefPubMedGoogle Scholar
  2. 2.
    Tremante E, Ginebri A, Lo Monaco E, Frascione P, Di Filippo F, Terrenato I, Benevolo M, Mottolese M, Pescarmona E, Visca P, Natali PG, Giacomini P (2012) Melanoma molecular classes and prognosis in the postgenomic era. Lancet Oncol 13(5):e205–211. doi: 10.1016/S1470-2045(12)70003-7 CrossRefPubMedGoogle Scholar
  3. 3.
    Carmona FJ, Esteller M (2011) Moving closer to a prognostic DNA methylation signature in colon cancer. Clin Cancer Res 17(6):1215–1217. doi: 10.1158/1078-0432.CCR-10-3446 CrossRefPubMedGoogle Scholar
  4. 4.
    Wu C, Morris JR (2001) Genes, genetics, and epigenetics: a correspondence. Science 293(5532):1103–1105CrossRefGoogle Scholar
  5. 5.
    Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990):457–463CrossRefPubMedGoogle Scholar
  6. 6.
    Kanwal R, Gupta S (2012) Epigenetic modifications in cancer. Clin Genet 81(4):303–311CrossRefPubMedGoogle Scholar
  7. 7.
    Adams RL, Burdon RH (1982) DNA methylation in eukaryotes. CRC Crit Rev Biochem 13(4):349–384CrossRefPubMedGoogle Scholar
  8. 8.
    Boyes J, Bird A (1991) DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. Cell 64(6):1123–1134CrossRefPubMedGoogle Scholar
  9. 9.
    Futscher BW, Oshiro MM, Wozniak RJ, Holtan N, Hanigan CL, Duan H, Domann FE (2002) Role for DNA methylation in the control of cell type specific maspin expression. Nat Genet 31(2):175–179CrossRefPubMedGoogle Scholar
  10. 10.
    Barlow DP (1995) Gametic imprinting in mammals. Science 270(5242):1610–1613CrossRefPubMedGoogle Scholar
  11. 11.
    Goto T, Monk M (1998) Regulation of X-chromosome inactivation in development in mice and humans. Microbiol Mol Biol Rev 62(2):362–378PubMedGoogle Scholar
  12. 12.
    Feinberg AP, Vogelstein B (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301(5895):89–92CrossRefPubMedGoogle Scholar
  13. 13.
    Qu GZ, Ehrlich M (1999) Demethylation and expression of methylated plasmid DNA stably transfected into HeLa cells. Nucleic Acids Res 27(11):2332–2338CrossRefPubMedGoogle Scholar
  14. 14.
    Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349(21):2042–2054CrossRefPubMedGoogle Scholar
  15. 15.
    Jones PA (2002) DNA methylation and cancer. Oncogene 21(35):5358–5360CrossRefPubMedGoogle Scholar
  16. 16.
    Sigalotti L, Covre A, Fratta E, Parisi G, Colizzi F, Rizzo A, Danielli R, Nicolay HJ, Coral S, Maio M (2010) Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med 8:56CrossRefPubMedGoogle Scholar
  17. 17.
    Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA (2009) Main roads to melanoma. J Transl Med 7:86CrossRefPubMedGoogle Scholar
  18. 18.
    Freedberg DE, Rigas SH, Russak J, Gai W, Kaplow M, Osman I, Turner F, Randerson-Moor JA, Houghton A, Busam K, Timothy BD, Bastian BC, Newton-Bishop JA, Polsky D (2008) Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst 100(11):784–795CrossRefPubMedGoogle Scholar
  19. 19.
    Tanemura A, Terando AM, Sim MS, van Hoesel AQ, de Maat MF, Morton DL, Hoon DS (2009) CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 15(5):1801–1807, doi:1078-0432.CCR-08-1361 [pii] 10.1158/1078-0432.CCR-08-1361CrossRefPubMedGoogle Scholar
  20. 20.
    Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B (2004) Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23(22):4014–4022CrossRefPubMedGoogle Scholar
  21. 21.
    Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343(19):1350–1354CrossRefPubMedGoogle Scholar
  22. 22.
    Ehrlich M (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21(35):5400–5413CrossRefPubMedGoogle Scholar
  23. 23.
    Schulz WA, Elo JP, Florl AR, Pennanen S, Santourlidis S, Engers R, Buchardt M, Seifert HH, Visakorpi T (2002) Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer 35(1):58–65CrossRefPubMedGoogle Scholar
  24. 24.
    Fratta E, Sigalotti L, Colizzi F, Covre A, Nicolay HJ, Danielli R, Fonsatti E, Altomonte M, Calabro L, Coral S, Maio M (2010) Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. J Cell Physiol 223(2):352–358. doi: 10.1002/jcp.22040 PubMedGoogle Scholar
  25. 25.
    Lahtz C, Stranzenbach R, Fiedler E, Helmbold P, Dammann RH (2010) Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. J Invest Dermatol 130(2):620–622, doi:jid2009226 [pii] 10.1038/jid.2009.226CrossRefPubMedGoogle Scholar
  26. 26.
    You Y, Ma L, You M, Li X, Wang S, Li H, Wu D, Yang H, Li ZY (2010) TSLC1 gene silencing in cutaneous melanoma. Melanoma Res 20(3):179–183. doi: 10.1097/CMR.0b013e32833413c0 PubMedGoogle Scholar
  27. 27.
    Schraml P, von Teichman A, Mihic-Probst D, Simcock M, Ochsenbein A, Dummer R, Michielin O, Seifert B, Schlappi M, Moch H, von Moos R (2012) Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncol Rep 28(2):654–658. doi: 10.3892/or.2012.1826 PubMedGoogle Scholar
  28. 28.
    Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, Busam K, Smith K, Orlow I, Panageas K, Chapman PB (2008) Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 26(14):2299–2304. doi: 10.1200/JCO.2007.14.5292 CrossRefPubMedGoogle Scholar
  29. 29.
    Hassel JC, Sucker A, Edler L, Kurzen H, Moll I, Stresemann C, Spieth K, Mauch C, Rass K, Dummer R, Schadendorf D (2010) MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer 103(6):820–826. doi: 10.1038/sj.bjc.6605796 CrossRefPubMedGoogle Scholar
  30. 30.
    Mori T, Martinez SR, O’Day SJ, Morton DL, Umetani N, Kitago M, Tanemura A, Nguyen SL, Tran AN, Wang HJ, Hoon DS (2006) Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res 66(13):6692–6698, doi:66/13/6692 [pii] 10.1158/0008-5472.CAN-06-0801CrossRefPubMedGoogle Scholar
  31. 31.
    Mori T, O'Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K, Kuo C, Takeshima TL, Milford R, Wang HJ, Vu VD, Nguyen SL, Hoon DS (2005) Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 23(36):9351–9358, doi:23/36/9351 [pii] 10.1200/JCO.2005.02.9876CrossRefPubMedGoogle Scholar
  32. 32.
    Sigalotti L, Covre A, Fratta E, Parisi G, Sonego P, Colizzi F, Coral S, Massarut S, Kirkwood JM, Maio M (2012) Whole genome methylation profiles as independent markers of survival in stage iiic melanoma patients. J Transl Med 10(1):185. doi: 10.1186/1479-5876-10-185 CrossRefPubMedGoogle Scholar
  33. 33.
    Sigalotti L, Fratta E, Bidoli E, Covre A, Parisi G, Colizzi F, Coral S, Massarut S, Kirkwood JM, Maio M (2011) Methylation levels of the "Long Interspersed Nucleotide Element-1" repetitive sequences predict survival of melanoma patients. J Transl Med 9(1):78. doi: 10.1186/1479-5876-9-78 CrossRefPubMedGoogle Scholar
  34. 34.
    Cordaux R, Batzer MA (2009) The impact of retrotransposons on human genome evolution. Nat Rev Genet 10(10):691–703. doi: 10.1038/nrg2640 CrossRefPubMedGoogle Scholar
  35. 35.
    Iacopetta B, Grieu F, Phillips M, Ruszkiewicz A, Moore J, Minamoto T, Kawakami K (2007) Methylation levels of LINE-1 repeats and CpG island loci are inversely related in normal colonic mucosa. Cancer Sci 98(9):1454–1460. doi: 10.1111/j.1349-7006.2007.00548.x CrossRefPubMedGoogle Scholar
  36. 36.
    Espina V, Wulfkuhle JD, Calvert VS, VanMeter A, Zhou W, Coukos G, Geho DH, Petricoin EF III, Liotta LA (2006) Laser-capture microdissection. NatProtoc 1(2):586–603CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, New York 2014

Authors and Affiliations

  1. 1.Cancer Bioimmunotherapy UnitCentro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere ScientificoAvianoItaly
  2. 2.Division of Medical Oncology and Immunotherapy, Department of OncologyUniversity Hospital of Siena, Istituto Toscano TumoriSienaItaly
  3. 3.Division of Medical Oncology and Immunotherapy, Department of OncologyIstituto Toscano Tumori, University Hospital of SienaSienaItaly

Personalised recommendations

Cite protocol

Buy options